Also known as: common epilepsies
Epilepsy is a chronic noncommunicable brain disorder characterized by recurrent unprovoked seizures due to abnormal electrical discharges in brain cells. Seizure manifestations vary widely in type, severity, and frequency. With appropriate diagnosis and treatment, many people can achieve seizure control.
The United Arab Emirates has unveiled two gene therapy projects targeting autism, epilepsy, and rare brain disorders in children. The initiatives focus on underlying genetic causes and earlier diagnosis.
Xenon Pharmaceuticals reported positive Phase III X-TOLE2 results for azetukalner in focal onset seizures. The company plans an FDA new drug application in Q3 2026.
The FDA has approved nivolumab with chemotherapy for pediatric and adult Hodgkin lymphoma patients aged 12+, based on clinical trial data showing improved survival. Separately, the agency cleared investigational new drug applications for FG001 for brain cancer surgery visualization and FRF-001 gene therapy for FOXG1 syndrome, allowing both to proceed to clinical trials.
The FDA has accepted Praxis Precision Medicines' NDA for relutrigine with priority review and set a PDUFA target date of September 27, 2026. The therapy targets SCN2A and SCN8A developmental and epileptic encephalopathies and could become the first approved treatment for these rare conditions. The company has bolstered its cash position to support commercial launch preparations.
The global generic drugs market reached $389 billion in 2024 and is projected to grow to $675 billion by 2033. In the U.S., generics account for 91% of prescriptions but only 18% of drug spending, saving over $373 billion annually. Biosimilar adoption remains below 20% despite some products reaching over 60% market share within three years.
New research reveals how ketamine rewires brain receptors to rapidly relieve severe depression, while separate trials demonstrate success with personalized brain stimulation and targeted drug therapy for treatment-resistant cases.
The FDA has authorized the first human trial of an allogeneic stem cell therapy for epilepsy, developed by Shanghai-based Unixell Biotechnology. The therapy uses donor-derived stem cells to produce GABA and suppress seizures in drug-resistant patients.
Xenon Pharmaceuticals will announce topline data from its Phase 3 X-TOLE2 study of azetukalner in patients with focal onset seizures on March 9, 2026, during a conference call at 8:00 a.m. ET.
New treatments for rare pediatric neurological conditions show promise, with zorevunersen reducing seizures in Dravet syndrome patients and an SMA therapy under FDA review following stem cell research breakthroughs.
Roche signed an agreement to invest $478 million in Korea clinical trials over five years, marking the largest foreign pharmaceutical investment. Korean companies are also securing pre-approval licensing deals globally, demonstrating growing competitiveness.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07599150 |
Intracranial CArtography of Cortical Contribution to Respiratory Load Compensation in Epilepsy |
NOT_YET_RECRUITING | NA |
| NCT07595666 |
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region. |
ENROLLING_BY_INVITATION | NA |
| NCT07594119 |
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures |
NOT_YET_RECRUITING | PHASE3 |
| NCT07592676 |
Transition From Pediatric to Adult Care in Epilepsy |
RECRUITING | |
| NCT07591350 |
Assessment of MRI-guided HIFU for Patients With Drug-resistant Focal Epilepsy |
NOT_YET_RECRUITING | NA |
| NCT07572812 |
A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy |
NOT_YET_RECRUITING | PHASE1 |
| NCT07568860 |
Sleep-Driven Adaptive Neuromodulation in Lennox-Gastaut Syndrome |
NOT_YET_RECRUITING | NA |
| NCT07563881 |
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 |
RECRUITING | PHASE3 |
| NCT07547501 |
PREDiction of Different Variants of Sleep Stages for the Diagnosis Support of Chronic Insomnia and Epilepsy |
NOT_YET_RECRUITING | |
| NCT07544563 |
Phenotypic Exploration During Sensory Stimulation in an Acoustic Chamber |
RECRUITING |
